Straumann Group account plan
Dental innovations and achievements
At a glance
Straumann Group is a Basel-based dental implant, orthodontics and digital dentistry company with 2025 revenue of CHF 2.6 billion and about 12 000 employees.
Straumann Group, headquartered in Basel, Switzerland, develops, manufactures and sells dental implants, prosthetics, clear aligners, biomaterials and digital equipment under brands including Straumann, Neodent, Medentika, Anthogyr and ClearCorrect. It sells to dentists, dental labs and dental service organizations (DSOs) in more than 100 countries from 18 production sites. FY2025 revenue was CHF 2 605.4 million (+8.9% organic), with core EBIT of CHF 655.5 million (25.2% margin) and IFRS net profit of CHF 358.0 million. Year-end 2025 headcount was 11 824. The company is listed in Switzerland, with a market capitalization of CHF 14 903 million at end-2025.
Business units
Sales EMEA
41.6% of FY2025 revenue (CHF 1 084.2 million)The largest region, grown 11.2% organically in 2025 on premium and challenger implants, intraoral scanners and integrated workflows. Q3 2026 organic growth was 10.5%, with DACH, Poland, Romania and Hungary contributing. Led by Holger Haderer.
Sales North America
26.4% of FY2025 revenue (CHF 687.7 million)Own distribution in the US and Canada plus ClearCorrect production, in a soft market with cautious patient spending. Organic growth was 4.2% in 2025 and 7.5% in Q3 2026, helped by DSOs and premium implants. Led by Grant Bester since April 2025.
Sales Asia Pacific
23.0% of FY2025 revenue (CHF 599.7 million)Own distribution and distributors plus AlliedStar scanners and T-Plus implants; India, Japan and Southeast Asia grow strongly. China slowed ahead of volume-based procurement (VBP 2.0) but returned to growth in Q3 2026. Led by Patrick Loh.
Sales Latin America
9.0% of FY2025 revenue (CHF 233.7 million)Driven by Neodent, with production in Brazil; grew 18.3% organically in 2025 but moderated to 6.5% in Q3 2026 as Brazilian patient flow slowed. Led by Alexei Costa, President Neodent.
Operations
Centralized manufacturing, logistics and supply chain with no third-party revenue but the largest segment operating profit; covers implant components, CADCAM milling centers and biomaterials. Led by COO Sébastien Roche.
Strategic priorities
- Expand implant leadership
- Grow share in a CHF 6.1 billion implant market where Straumann holds above 35%, led by iEXCEL (close to 40% of premium implant volumes in H1 2026) and challenger brand Neodent.
- Digital ecosystem around scanners
- Use intraoral scanners as the gateway to the Straumann AXS cloud platform, which has more than 20 000 active users; AXS users show substantially higher reorder rates.
- Transform orthodontics
- Refocus ClearCorrect on general practitioners and DSOs, with production moved to the Smartee platform and break-even targeted by the end of 2027.
- Win DSOs
- A tiered coverage model and consultative selling for DSOs; roughly 20% of implants are placed by DSO-affiliated practitioners, expected to reach as much as 30% in major markets by 2029.
- Margin expansion to 2030
- Around 10% average annual revenue growth over the mid term and 40 to 50 basis points of annual core EBIT margin increase at constant currency until 2030, supported by the "Unlocking value" initiative.
Latest results
Q3 2026 revenue was CHF 667.1 million, up 9.2% organically and 10.8% in Swiss francs, bringing nine-month revenue to CHF 2 046.5 million (+8.3% organic). In H1 2026, revenue was CHF 1 379.5 million (+7.8% organic) with a core EBIT margin of 25.7% (26.9% at constant 2025 rates) and free cash flow of CHF 169 million. All regions contributed, with EMEA and APAC growing double-digit in Q3, while Latin America moderated. The 2026 outlook was confirmed in October: high single-digit organic revenue growth and core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates.
Investments and deals
- Manufacturing capacity
- Over CHF 1 billion went into manufacturing capacity over four years; 2025 capex was CHF 223.5 million, mainly in Shanghai, Curitiba, Calw and Villeret, and implant capacity doubles by 2026.
- Third Neodent factory
- The third Neodent factory in Curitiba, Brazil, opened in September 2026.
- Villeret center of excellence
- CHF 60 to 80 million committed over five years to make Villeret a center of excellence for precision manufacturing and automation.
- Acquisitions in ceramics and AI
- maxon dental GmbH went to full ownership in June 2025 and became Straumann Ceramic; full ownership of Promaton (AI for dental applications) followed in 2025.
- Headquarters move
- The headquarters is planned to move to Arlesheim, Switzerland.
Challenges and risks
- China volume-based procurement
- China saw a double-digit decline from Q3 2025 ahead of VBP 2.0, whose implementation is anticipated in Q1 2027.
- Tariffs and currency
- Tariffs cost around CHF 20 million in 2025 COGS, and FX is expected to have an 80 to 100 bps negative impact on the 2026 EBIT margin.
- Soft consumer demand
- North America faces cautious consumer sentiment, and Brazilian patient flow through large dental groups lost momentum in Q3 2026.
- Orthodontics losses
- ClearCorrect is not yet profitable, with break-even targeted for the end of 2027 and a German plant closure in the transition.
- Leadership transition and litigation
- CEO Guillaume Daniellot leaves at the end of 2026, succeeded by Christopher Norbye, and H1 2026 carried CHF 18.0 million of legal costs from the Align Technology litigation.
What leadership says
“Continued share gains for iEXCEL reinforce our leadership in premium implantology, while Neodent keeps on expanding access to treatment in more markets”
“Every digital workflow in our ecosystem starts with a scan.”
“In today's dental market, product performance alone is no longer sufficient.”
“at least two-thirds of the improvement we have seen is structural”
Where a supplier can help
- Precision manufacturing and automation
- The Villeret center of excellence, the new Curitiba factory and doubled implant capacity call for machining, automation and quality equipment.
- Digital and AI platform partners
- Scaling Straumann AXS and AI case assessment opens room for cloud, data and software partners tied to the digital ecosystem priority.
- Supply chain and tariff mitigation
- Tariff costs and the shift to local-for-local production create needs for trade, logistics and supply chain tools.
- Efficiency programmes
- The "Unlocking value" initiative (procurement, operations excellence, working capital) and disciplined OpEx favour suppliers that cut cost.
- DSO selling and CRM
- The DSO priority and consultative selling model can use sales enablement, CRM and education tooling.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Straumann Group?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Straumann Group Annual Report 2025
- Straumann Group (Basel, SIX: STMN) is the global leader in dental implantology with an estimated implant market share above 35%, and also sells clear aligners (ClearCorrect), biomaterials, CADCAM prosthetics and digital equipment (SIRIOS intraoral scanners, Straumann AXS cloud platform); about 12 000 employees, 18 production sites, more than 100 countries.
- FY2025 revenue CHF 2 605.4 million: organic growth 8.9% but only 4.1% in Swiss francs, as currency headwinds lowered revenue by more than CHF 100 million.
- Core EBIT CHF 655.5 million; core EBIT margin 25.2% reported, 26.5% at constant 2024 currencies. IFRS EBIT CHF 549.2 million and net profit CHF 358.0 million, hit by restructuring (CHF 40 million), legal costs (CHF 24 million) and HQ relocation impairment (CHF 7 million).
- Regions: EMEA CHF 1 084.2 million (41.6% of revenue, +11.2% organic), North America CHF 687.7 million (26.4%, +4.2%), Asia Pacific CHF 599.7 million (23.0%, +7.3%; China softened before VBP 2.0), Latin America CHF 233.7 million (9.0%, +18.3%).
- New "Go Beyond" strategy phase: expand implant leadership (iEXCEL passed one million implants sold), win strategic customer groups (DSOs), transform the ortho franchise (Smartee and DentalMonitoring partnerships), transform the dental professional's digital experience; addressable market around CHF 20 billion.
- Mid-term targets: around 10% average annual revenue growth and an average 40 to 50 basis points core EBIT margin increase per year at constant currencies until 2030; dividend proposed CHF 1.00 per share.
- Capex CHF 223.5 million in 2025 (Shanghai campus, third Neodent plant in Curitiba, Calw, Villeret), with implant capacity set to double by 2026 and a period of lower capex intensity ahead; free cash flow CHF 290.2 million.
- Leadership: Chair Petra Rumpf, CEO Guillaume Daniellot; CFO Isabelle Wege joined in July 2025; founder Thomas Straumann becomes Honorary Chairman.
- Main risks named: pricing pressure (China VBP, DSO consolidation), capacity and supply chain, tariffs and geopolitics, regulation, IP, cybersecurity and foreign exchange.
- Straumann Group Half-Year Report 2026 (media release and interim financial information)
- H1 2026 revenue CHF 1 379.5 million: +7.8% organic, +2.3% in Swiss francs; Q2 revenue CHF 707.0 million, organic growth up to 8.5%.
- Core EBIT CHF 354.8 million; core EBIT margin 26.9% at constant 2025 exchange rates, 25.7% including currency effects. Core net profit CHF 262.0 million; IFRS net profit CHF 250.7 million.
- Free cash flow up 49% to CHF 168.6 million as capex fell to CHF 74.1 million (CHF 113.0 million a year earlier) after the capacity-investment cycle.
- Q2 organic growth by region: EMEA +8.6%, North America +8.4%, Asia Pacific +7.4% (+25.0% excluding China), Latin America +11.8%.
- iEXCEL represented close to 40% of Straumann premium implant volumes; intraoral scanners (SIRIOS X3) and Straumann AXS users grew strongly; Neodent expanded geographically.
- ClearCorrect's EMEA and APAC production moved to Smartee, keeping it on course to break even by the end of 2027.
- China: sequential improvement; VBP 2.0 expected to start its process in H2 2026 with operational execution in very early 2027. The Shanghai campus localizes production and Medentika launched a China implant line.
- Outlook 2026 (upgraded in June) confirmed: high single-digit organic growth and core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates.
- The Align Technology US patent and antitrust trial ended in June 2026 with neither party found liable; legal costs were CHF 18.0 million in H1.
- Straumann Group Q3 2026 results: organic growth accelerates to 9.2%, full-year 2026 outlook confirmed
- Q3 2026 revenue CHF 667.1 million: +9.2% organic, +10.8% in Swiss francs. Nine-month revenue CHF 2 046.5 million, +8.3% organic.
- Q3 by region: EMEA CHF 256.0 million (+10.5% organic), North America CHF 174.9 million (+7.5%), Asia Pacific CHF 165.6 million (+10.3%), Latin America CHF 70.5 million (+6.5%, moderating as Brazil slowed).
- China returned to growth after several quarters of VBP uncertainty; VBP 2.0 rules are not yet published and implementation is anticipated in Q1 2027.
- Launch of Straumann F.A.S.T. digital implant workflows, including SIRIOS APS for full-arch scanning on iEXCEL implants.
- Straumann AXS now has more than 20 000 active users, and AXS users reorder substantially more than non-users.
- ClearCorrect grew double-digit in its priority markets and remains on track to break even by the end of 2027.
- A third Neodent factory opened in Curitiba in September.
- Guidance confirmed for 2026: high single-digit organic growth, core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates.
- CEO Guillaume Daniellot hands over to Christopher Norbye; Renata Putnik becomes Chief People Officer on January 1, 2027, succeeding Arnoud Middel.
- Straumann Group half-year 2026 results conference call (transcript)
- Half-year 2026 results call (19 August 2026) with CEO Guillaume Daniellot and CFO Isabelle Wege; Daniellot confirmed he will leave at the end of the year after almost 20 years at the company, seven as CEO, and that successor Christopher Norbye agrees with the mid-term guidance.
- Q2 organic growth 8.5% and H1 7.8%; core EBIT margin 26.9% at constant 2025 rates; flat headcount with 8% growth.
- CFO: at least two-thirds of the margin improvement is structural; the rest is tailwind from lower tariffs and the later VBP 2.0. The 2030 ambition of 40 to 50 bps average annual margin expansion is unchanged and progress should continue "well into 2027".
- FX: at July spot rates, an expected 80 to 100 basis points negative impact on the 2026 EBIT margin.
- China VBP 2.0: CEO expects a maximum -5% to -15% ASP decrease, a low comparison base, and a return to low-to-mid-teens growth; Shanghai campus fully operational and Neodent registration planned for 2027.
- Digital: Straumann estimates it sells one-fourth to one-third of intraoral scanner units; AXS user base growing double-digit; iEXCEL close to 40% of premium implant volumes.
- ClearCorrect on track to break even by end 2027 after the move of production to Smartee; North America expected at 6% to 9% growth in H2, more on the high single digit.
- Straumann Group full-year 2025 results conference call (transcript)
- Full-year 2025 results call (18 February 2026) with CEO Guillaume Daniellot and the CFO: revenue CHF 2.6 billion, +8.9% organic, core EBIT margin 25.2% (26.5% at constant currency), more than 7.3 million smiles.
- Market share within the CHF 20 billion addressable market rose from 12.5% to 14% in 12 months; implantology share above 35%, digital equipment above 10%, clear aligners and CADCAM prosthetics below 5%.
- Three strategic priorities: expand implant leadership, transform orthodontics (Smartee, DentalMonitoring), disrupt chairside prosthetics (SprintRay, Straumann Signature MIDAS).
- iEXCEL: more than 1 million implants sold, "the most successful product launch in our history"; Neodent sold around 5 million Grand Morse implants in 2025 and should be registered in China by 2027.
- Straumann AXS went from zero to more than 15,000 active users in 18 months; the Fast Molar workflow cuts appointments from 5 to 2.
- Initial 2026 guidance: high single-digit organic growth and 30 to 60 bps core EBIT margin improvement at constant 2025 rates, H2-weighted (China VBP, Smartee transfer, tariffs).
- Capex: over CHF 1 billion invested in manufacturing in four years; implant capacity doubled with Curitiba 3, so capex steps down in 2026 and again in 2027.
- Tariffs cost around CHF 20 million in 2025 COGS, with a similar amount expected in 2026; ClearCorrect targeted to break even by end 2027.
Questions about Straumann Group
What does Straumann Group do?
Straumann develops, manufactures and sells dental implants, prosthetics, clear aligners, biomaterials and digital dentistry equipment such as intraoral scanners, under brands including Straumann, Neodent and ClearCorrect.
What is Straumann Group's revenue?
FY2025 revenue was CHF 2 605.4 million, up 8.9% organically; nine-month 2026 revenue was CHF 2 046.5 million.
How many employees does Straumann Group have?
Headcount was 11 824 at end-2025 and 11 582 at the end of June 2026.
What is Straumann Group's strategy?
Under "Go Beyond" it aims to expand implant leadership, win DSOs, transform orthodontics and grow its digital ecosystem, targeting around 10% annual revenue growth over the mid term.
Who leads Straumann Group?
Guillaume Daniellot is CEO until the end of 2026, when Christopher Norbye succeeds him; Isabelle Wege is CFO and Petra Rumpf chairs the Board.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)